---
document_datetime: 2024-01-15 11:59:32
document_pages: 7
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/intrarosa-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: intrarosa-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 4.5683687
conversion_datetime: 2025-12-29 21:44:37.475634
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Intrarosa

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                     | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|----------------------|---------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSR/S/0044           | Post Authorisation Safety Study results - EMEA/H/C/PSR/S/0044 - Variation | 12/10/2023                          | 07/12/2023                                  | SmPC, Annex II and PL            | Intrarosa (prasterone) is removed from the additional monitoring list as the condition to the marketing authorisation has been fulfilled. This relates to the non- interventional PASS - Drug Utilisation Study (DUS) to describe the baseline characteristics, utilisation patterns of EU postmenopausal women initiating treatment with Intrarosa and to assess whether EU prescribers abide by the contraindications stated in the EU SmPC. |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |            |            |                       | Therefore, the statement that this medicinal product is subject to additional monitoring and that this will allow quick identification of new safety information, preceded by an inverted equilateral black triangle, is removed from the summary of product characteristics and the package leaflet.   |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0024/G           | This was an application for a group of variations. B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the originally approved batch size B.II.e.4.a - Change in shape or dimensions of the container or closure (immediate packaging) - Non- sterile medicinal products A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) | 30/10/2023 | n/a        |                       |                                                                                                                                                                                                                                                                                                         |
| IA/0023             | B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect the product information                                                                                                                                                                                                                                                                                                                                                                | 24/10/2022 | n/a        |                       |                                                                                                                                                                                                                                                                                                         |
| R/0022              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 21/07/2022 | 15/09/2022 | SmPC, Annex II and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Intrarosa in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity.                                 |
| PSUSA/10672 /202111 | Periodic Safety Update EU Single assessment - prasterone (vaginal use/Pessary)                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 10/06/2022 | n/a        |                       | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

| IB/0020   | B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                           | 07/03/2022   | n/a        |          |                          |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------|--------------------------|
| IB/0018   | To update the RMP with the final amended protocol of the non-interventional PASS - Drug Utilisation Study. Annex IID is updated accordingly. In addition minor changes have been introduced in the RMP to reflect previous approvals in other variations. C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing the RMP - Other variation                                                                                                                                                                       | 20/01/2022   | 15/09/2022 | Annex II | authorisation, including |
| IA/0019/G | This was an application for a group of variations. B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) B.II.c.1.c - Change in the specification parameters and/or limits of an excipient - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) | 14/01/2022   | n/a        |          |                          |
| II/0015   | B.I.a.1.b - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS -                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 16/12/2021   | n/a        |          |                          |

<div style=\"page-break-after: always\"></div>

|                     | Introduction of a manufacturer of the AS supported by an ASMF                                                                                                                                                                                                                                                                                                                                     |            |     |                                   |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| PSUSA/10672 /202105 | Periodic Safety Update EU Single assessment - prasterone (vaginal use/Pessary)                                                                                                                                                                                                                                                                                                                    | 02/12/2021 | n/a | PRAC Recommendation - maintenance |
| PSUSA/10672 /202011 | Periodic Safety Update EU Single assessment - prasterone (vaginal use/Pessary)                                                                                                                                                                                                                                                                                                                    | 10/06/2021 | n/a | PRAC Recommendation - maintenance |
| IB/0014             | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                                                                                                                                      | 29/01/2021 | n/a |                                   |
| PSUSA/10672 /202005 | Periodic Safety Update EU Single assessment - prasterone (vaginal use/Pessary)                                                                                                                                                                                                                                                                                                                    | 14/01/2021 | n/a | PRAC Recommendation - maintenance |
| PSUSA/10672 /201911 | Periodic Safety Update EU Single assessment - prasterone (vaginal use/Pessary)                                                                                                                                                                                                                                                                                                                    | 11/06/2020 | n/a | PRAC Recommendation - maintenance |
| IA/0011/G           | This was an application for a group of variations. B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.I.d.1.b.1 - Stability of AS - Change in the storage conditions - Change to more restrictive storage conditions of the AS | 17/01/2020 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

| PSUSA/10672 /201905   | Periodic Safety Update EU Single assessment - prasterone (vaginal use/Pessary)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 28/11/2019   | n/a        |    | PRAC Recommendation - maintenance   |
|-----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----|-------------------------------------|
| N/0010                | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 04/11/2019   | 01/04/2020 | PL |                                     |
| IB/0008/G             | This was an application for a group of variations. B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch- release, batch control, primary and secondary packaging, for non-sterile medicinal products B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.b.1.a - Replacement or addition of a | 05/09/2019   | n/a        |    |                                     |

<div style=\"page-break-after: always\"></div>

|                     | site B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place   |            |            |                        |                                   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------|
| PSUSA/10672 /201811 | Periodic Safety Update EU Single assessment - prasterone (vaginal use/Pessary)                                                                                                                                                                                                     | 14/06/2019 | n/a        |                        | PRAC Recommendation - maintenance |
| IAIN/0007           | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                 | 17/05/2019 | n/a        |                        |                                   |
| IAIN/0006/G         | This was an application for a group of variations. A.6 - Administrative change - Change in ATC Code/ATC Vet Code B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                | 16/04/2019 | 01/04/2020 | SmPC                   |                                   |
| T/0005              | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                | 05/02/2019 | 11/03/2019 | SmPC, Labelling and PL |                                   |
| PSUSA/10672 /201805 | Periodic Safety Update EU Single assessment - prasterone (vaginal use/Pessary)                                                                                                                                                                                                     | 29/11/2018 | n/a        |                        | PRAC Recommendation - maintenance |

<div style=\"page-break-after: always\"></div>

| IA/0003/G   | was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 04/10/2018   | n/a        |                 | This                   |
|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------|------------------------|
| IAIN/0002/G | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.2.c.2 - Change to importer, batch release arrangements and quality control testing of the FP - Including batch control/testing B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier B.IV.1.a.1 - Change of a measuring or administration device - Addition or replacement of a device which is not an integrated part of the primary packaging - | 04/10/2018   | 11/03/2019 | Annex II and PL | Device with CE marking |